PET-based evaluation of short-term amyloid-β clearance and predictive factors in real-world Alzheimer's disease patients treated with lecanemab. (PubMed, J Alzheimers Dis) - Oct 9, 2026 - "Baseline amyloid burden and treatment exposure predicted greater clearance; tau showed attenuating trend. Visual-quantitative discordance supports a hybrid PET pathway: visual screening for inclusivity, serial CL quantification for monitoring, and combined assessment for low-CL patients."
Biomarker • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders
|
|
Guihong Wang; Lin Ai; Shen Li; Tenghong Lian; Xiaobin Zhao; Zhen Qiao
|